查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数字糖尿病管理市场-2022-2029
市场调查报告书
商品编码
1140718

全球数字糖尿病管理市场-2022-2029

Global Digital Diabetes Management Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

数字糖尿病管理市场规模预计将在 2021 年达到 118.4 亿美元，到 2029 年达到 297.6 亿美元，在预测期间（2022-2029 年）以 13.65% 的复合年增长率增长。

糖尿病是一种由高血糖引起的代谢性疾病。它的发生是因为胰腺要么不能产生足够的胰岛素，要么身体不能有效地利用胰岛素。它的特点是口渴和排尿增加、饥饿感增加、疲劳、视力模糊、腿和手麻木、持续疼痛和无法解释的体重减轻。据说肥胖、高血压、心脏病、抑郁症和缺乏运动会增加患糖尿病的风险。数字糖尿病管理系统用于通过降低和维持低血糖水平来改善自我管理和控製糖尿病。

市场动态

由于糖尿病患者患病率上升等因素，全球数字糖尿病管理市场正在增长，老年人口不断增加，久坐不动的生活方式，肥胖和新技术进步推动了市场增长。

糖尿病患病率的上升和各种新技术的进步预计将推动市场增长。

糖尿病患者患病率的上升，以及老年人口、久坐不动的生活方式和肥胖症的增加，将推动市场增长。根据国际糖尿病联合会的数据，全世界约有 4.63 亿 20-79 岁的成年人患有糖尿病。预计到 2045 年，这一数字将增加到 7 亿。

市场继续看到新的数字糖尿病药物的推出和批准。例如，2022 年 5 月，Roche diabetes care推出了 Accu-Fine，这是一种笔形针头，可实现平稳、几乎无痛的胰岛素给药。它旨在通过使糖尿病患者更容易使用胰岛素来改善糖尿病管理。

2022 年 6 月， Abbott正在开发一种新的生物仪器，该仪器将通过一个传感器持续监测葡萄糖和酮水平。该系统已获得美国 FDA 的突破性设备指定，将使危及生命的人们的生活更加舒适。

该市场以技术先进的产品为主，例如连续血糖监测仪、结合泵和监测仪以算法实现胰岛素给药自动化的系统、远程医疗患者护理产品和人工胰腺。例如，在 2021 年 2 月，Medtronic的 InPen 智能胰岛素笔和 Guardian 4 将获得 CE 标誌，该传感器是一种不需要手指棒来做出糖尿病治疗决定的传感器，还将获得 CE 标誌。已宣布。这允许传感器与 InPen 和 MiniMed 780G 集成，用于连续血糖监测。

糖尿病管理产品的高成本阻碍了市场增长

市场受到数字糖尿病管理产品高价的阻碍，例如智能手机连接的胰岛素泵、基于传感器的连续血糖仪和数字自我监测设备。此外，一些国家存在不利的报销方案也将阻碍市场增长。报销政策的差异，特别是在印度和中国等新兴国家，往往导致治疗不依从。

行业分析

全球数字糖尿病管理市场根据波特五力、监管分析、供应链分析和定价分析等各种行业因素对市场进行了深入分析。

细分分析

产品和服务部门在数字糖尿病管理全球市场中占据最大市场份额

全球数字糖尿病管理市场按产品/服务类型细分为设备、数字糖尿病管理应用程序、数据管理软件和平台以及服务。设备部分占据了最高的市场份额。设备部分包括智能血糖仪、连续血糖监测（CGM）系统、智能胰岛素笔、智能胰岛素泵/闭环泵、智能胰岛素贴片等。由于与智能设备的兼容性，连续血糖监测系统占有最高的市场份额。由于与用作显示设备的智能设备兼容，我们的连续血糖监测系统占据了近 40.0% 的最大市场份额。它还可以设置为在达到某些葡萄糖阈值时向患者发送自定义警报。连续血糖监测设备使用插入皮下的传感器。血糖读数每 1-5 分钟会出现在显示器上。该设备允许在达到某些葡萄糖阈值时向患者发送自定义警报。该市场主要由美国食品和药物管理局 (FDA) 批准的产品的可用性主导，例如DexCom G4 Platinum、Medtronic Diabetes Guardian Real-Time、Medtronic Diabetes MiniMed Paradigm Real-Time Revel，它们是连续血糖监测仪和胰岛素泵。 .

由于开发智能胰岛素笔的公司太多，预计智能胰岛素笔细分市场将出现积极的市场增长。智能胰岛素笔的推出正在兴起。例如，2020 年 11 月，Medtronic在收购 Companion Medical 后推出了与公司 Guardian Connect 血糖监测系统集成的 InPen 设备。InPen 是第一个也是唯一一个获得 FDA 批准的解决方案，包括一个胰岛素注射器笔、一个直观的智能手机应用程序和一个使用蓝牙技术的推注顾问。可用于胰岛素剂量跟踪，包括启动。它还自动将数据发送到用户的移动设备，为成功进行胰岛素治疗所需的持续监测和计算提供决策支持。

此外，市场按设备类型分为手持设备和可穿戴设备。由于可穿戴数字糖尿病管理设备具有可访问性、可扩展性和随处测试等优势，可穿戴设备的市场份额最大。诸如引入人工智能、增加采用自我管理的胰岛素输送设备、闭环泵系统和智能胰岛素贴片等技术进步正在上升。

区域分析

北美在数字糖尿病管理全球市场中占有最大份额

按地区划分，全球数字糖尿病管理市场分为北美、南美、欧洲、亚太地区、中东和非洲。在所有地区中，由于糖尿病的高发病率，北美在全球数字糖尿病管理市场中占据主导地位。根据美国糖尿病协会 (ADA) 的数据，每年约有 150 万美国人被诊断出患有糖尿病。到 2022 年，大约 3730 万人或美国人口的 11.3% 将患有糖尿病。预计数字糖尿病管理产品开发的技术进步将刺激市场。有利的报销政策和更好的医疗保健设施的存在将推动市场的增长。

由于糖尿病患者的增加，预计亚太地区市场将出现积极扩张。根据亚洲糖尿病预防倡议，全球 60% 的糖尿病患者生活在亚洲（2020 年）。印度和中国等新兴国家在亚洲的糖尿病患病率很高。中国约有 1390 万成年人，即成年人口的 11.6%，患有糖尿病。印度约有 6510 万成年人患有糖尿病。到 2030 年，中国和印度预计将有近 5 亿糖尿病患者。一些组织、团体和研究机构正在提高对糖尿病患者的管理、诊断和治疗的认识。技术进步、医疗保健投资的增加以及研发活动的增加预计将刺激市场增长。

竞争格局

由于存在多个国际和国内市场，全球数字糖尿病管理市场竞争激烈。产品多样化、创收和机会使市场更具竞争力。Medtronic Plc、F. Hoffmann-La Roche Dexcom, Inc.、Abbott Laboratories、B. Braun Melsungen AG、Lifescan, Inc.（Subsidiary of Johnson &Johnson）和 Agamatrix, Inc. 是主要的市场参与者，拥有重要的市场份额。

公司利用新产品发布、产品开发、市场扩张和技术进步的战略来维持其在市场中的地位。

公司正在开展合作、合併、战略伙伴关係和收购，以增加对数字糖尿病管理的需求并在全球范围内扩张。例如，2019 年 9 月，Medtronic与Novo Nordisk合作，提供结合各自技术的数字解决方案，帮助糖尿病患者更好地管理健康。根据协议，Medtronic的连续血糖监测（CGM）设备，包括 Guardian Connect 系统，将整合目前与Novo Nordisk共同开发的智能胰岛素笔的胰岛素剂量数据。

2022年7月，提供胰岛素输送和糖尿病相关技术的Tandem Diabetes Care宣布收购输液器开发商Capillary Biomedical。

8 月，无内胎胰岛素泵技术的领导者 Insulet Corporation 宣布美国 FDA 批准 Omnipod 5，这是一种用于 2 岁及以上患有 1 型糖尿病的儿童的自动胰岛素输送系统。

每家公司都筹集和投资以提高市场渗透率。例如，2020 年 1 月，Virta 筹集了 9300 万美元的 C 轮融资，以扩大其数字糖尿病产品和覆盖范围。

值得关注的重点公司

Medtronic Plc：

概述 Medtronic plc 是一家总部位于美国明尼阿波利斯的製造和销售医疗器械的美国公司。它在大约 140 个国家开展业务，拥有 90,000 名员工。

产品介绍

I-PORT ADVANCE：这是一个在皮下留有套管的注射口，因此插入时没有疼痛，并且可以每三天注射一次药物，只需少量穿刺。大人小孩都可以使用。

重大发展。2020年8月，医疗技术领导者Medtronic宣布收购InPen製造商Companion Medical——唯一获得美国FDA批准的智能胰岛素笔系统。

全球数字糖尿病管理市场报告提供了大约 45 个以上的市场数据表、40 多个数字和 180 页的内容。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

第四章市场动态

  • 市场影响因素
    • 促进者
      • 糖尿病患病率上升
      • 技术进步加快
    • 抑製剂
      • 用于糖尿病管理的数字设备成本高
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析

第 6 章按产品/服务分类

  • 设备
    • 智能血糖仪
    • 连续血糖监测 (CGM) 系统
    • 智能胰岛素笔
    • 智能胰岛素泵/闭环泵/智能胰岛素贴片
  • 数字糖尿病管理应用程序
    • 糖尿病/血糖管理应用程序
    • 体重和饮食管理应用
  • 数据管理软件和平台
  • 其他

第 7 章 按设备类型

  • 手持设备
  • 可穿戴设备

第 8 章最终用户

  • 自我/家庭保健
  • 医院和糖尿病诊所
  • 学术/研究机构
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 10 章 竞争格局

  • 主要发展和战略
  • 公司股份分析
  • 产品/服务基准测试
  • 值得关注的重点公司名单

第十一章公司简介

  • Medtronic Plc
    • 公司简介
    • 产品和服务的组合和内容
    • 主要亮点
    • 财务摘要
  • F. Hoffmann-La Roche Dexcom, Inc.
  • Dexcom, Inc.
  • Ascensia Diabetes Care Holdings Ag.
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Tidepool
  • Glooko, Inc.
  • Lifescan, Inc.（Subsidiary of Johnson & Johnson）
  • Agamatrix, Inc.

第 12 章全球数字糖尿病管理市场-DataM

简介目录
Product Code: DMMD2392

Market Overview

Digital Diabetes Management Market size was valued US$ 11.84 billion in 2021 and is estimated to reach US$ 29.76 billion by 2029, growing at a CAGR of 13.65% during the forecast period (2022-2029).

Diabetes is a metabolic disease that occurs due to high level of blood sugar levels. The result of either the pancreas does not produce enough insulin, or the body cannot effectively use the insulin it produces. It is characterized by the increased thirst and urination, increased hunger, fatigue, blurred vision, numbness or tingling in the feet or hands, sores that do not heal, and unexplained weight loss. Obesity, high blood pressure, heart disease, depression, physical inactivity, and others increase the risk of developing diabetes. The digital diabetes management system is used for improving self-management and controlling diabetes by reducing the blood glucose level and sustaining lower blood glucose.

Market Dynamics

The global digital diabetes management market is growing due to several factors such as the rising prevalence of diabetics drives the market growth with a rising geriatric population, sedentary lifestyle, and obesity. and novel technological advances.

Rising prevalence of diabetes and various new technological advancements are expected to drive market growth.

The rising prevalence of diabetics drives the market growth with a rising geriatric population, sedentary lifestyle, and obesity. According to the International Diabetes Federation, approximately 463 million adults of age-groups 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045.

The market is witnessing the launch and approval of novel digital diabetes products. For instance, in May 2022, Roche diabetes care launched Accu-Fine, pen needles that provides virtually painless and smooth process of insulin delivery. It aims to better diabetes management by making insulin delivery easier for diabetic patients.

In Jun 2022, Abbott is developing a novel biowearable that will monitor glucose & ketone levels continuously in 1 sensor. System has already received breakthrough device designation from U.S.FDA. that will make life easier of people with life-threatening conditions.

The market is dominated by the presence of technological advancement products, including continuous glucose monitors, the systems that combine both a pump and a monitor for algorithm-driven automation of insulin delivery, long-distance patient care products, and artificial pancreas. For instance, in Feb 2021, Medtronic announced it got CE Mark for InPen smart insulin pen that can be used for multiple daily injections and Guardian 4 sensor also received CE Mark that doesn't need fingersticks for diabetes treatment decisions. This now permits the integration of sensor with InPen or MiniMed 780G for continuous glucose monitoring.

High cost of diabetes management products is expected to hamper the market growth.

The market is hindered by the high cost of digital diabetes management products, including smartphone-connected insulin pumps, sensor-based continuous glucose monitors, Digital self-monitoring blood glucose meters, etc. Moreover, the presence of unfavorable reimbursement scenarios in few countries shall hamper the market growth. There are disparities in reimbursement policies that often result in non-compliance to treatment, especially in developing countries, including India and China.

Industry Analysis

The global digital diabetes management market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Product & service segment is expected to hold the largest market share in global digital diabetes management market

The global digital diabetes management market is segmented on product & service types as devices, digital diabetes management apps, data management software & platforms, and services. The devices segment accounts for the highest market share. The device segment includes smart glucose meters, continuous glucose monitoring (CGM) systems, smart insulin pens, smart insulin pumps/closed-loop pumps & smart insulin patches. The continuous blood glucose monitoring systems account for the highest market share due to their compatibility with smart devices. The continuous blood glucose monitoring systems segment held the largest market share of just under 40.0% owing to their compatibility with smart devices that serve as display devices. Moreover, they can also be set to send custom alerts to patients when certain glucose thresholds are reached. Continuous glucose monitoring devices involved the use of a sensor that is inserted under the skin. It provides glucose reading every one to five minutes on the monitor. It is possible to send custom alerts to patients when certain glucose thresholds are reached through this device. The market is dominated by the availability of the US Food and Drug Administration (FDA) approved products, including the DexCom G4 Platinum, Medtronic Diabetes Guardian Real-Time, and Medtronic Diabetes MiniMed Paradigm Real-Time Revel, which is a combination continuous glucose monitor and insulin pump.

The smart insulin pen segment is expected to have positive market growth, with too many companies developing the smart insulin pen. There is an increase in the launch of the smart insulin pen. For instance, in Nov 2020, Medtronic launched its InPen device integrated with its guardian connect glucose monitoring system after its acquisition of Companion Medical. InPen is the first and only FDA-cleared solution comprised of the insulin injector pen with an intuitive smartphone app and bolus advisor using bluetooth technology. It is effective in tracking insulin doses, including priming. It automatically sends the data to the user's mobile device, providing decision support for the constant monitoring and calculating necessary for successful insulin therapy.

Further, the market is also classified based on device type as handheld devices and wearable devices. The wearable devices segment accounts for the largest market share owing to the higher adoption of wearable digital diabetes management devices because of their advantages, such as better accessibility, scalability, and the ability to test anywhere. There is growing technological advancement, including the introduction of artificial intelligence, the growing adoption of self-administering insulin delivery devices, and closed-loop pump systems and smart insulin patches.

Geographical Analysis

North America region holds the largest market share in the global digital diabetes management market

By region, the global digital diabetes management market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global digital diabetes management market due to the high prevalence of diabetes. According to the American Diabetes Association (ADA), approximately 1.5 million Americans are diagnosed with diabetes every year. Around 37.3 million people, or 11.3% of the US population, have diabetes in 2022. The growing technological advancement for the development of digital diabetes management products shall stimulate the market. The presence of favourable reimbursement policies and better healthcare facilities shall fuel the market growth.

The Asia Pacific region is expected to have positive market growth owing to the increasing prevalence of diabetics. According to the Asian Diabetes Prevention Initiative, 60% of the world's diabetic population lives in Asia (2020). Developing countries such as India and China have a high prevalence of diabetics in Asia. Around 13.9 million adults, i.e., 11.6% of the adult population, have diabetes in China. Approximately 65.1 million adults with diabetes in India. It is expected that both China and India would have almost half a billion diabetic patients by 2030. Several organizations, associations, and institutes create awareness regarding the management, diagnosis, and treatment of diabetics. The growing technological advancement, rising healthcare investment, and increasing research and development activities shall stimulate market growth.

Competitive Landscape

The global digital diabetes management market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Medtronic Plc, F. Hoffmann-La Roche Dexcom, Inc., Abbott Laboratories, B. Braun Melsungen AG, Lifescan, Inc. (Subsidiary of Johnson & Johnson), and Agamatrix, Inc. are the leading market players with significant market share.

Companies are using the new product launch, product development, market expansion, and technological advancement strategies for holding their market position.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for digital diabetes management and their expansion across the globe. For instance, In September 2019, Medtronic had entered into a collaboration with Novo Nordisk to provide digital solutions that would combine their respective technologies to help diabetic patients better manage their condition. Under the terms of the agreement, Medtronic's continuous glucose monitoring (CGM) devices, including the Guardian Connect system, would integrate insulin dosing data from smart insulin pens currently in development with Novo Nordisk.

In Jul 2022, Tandem Diabetes Care, Inc., insulin delivery as well as diabetes technology company announced its acquisition of Capillary Biomedical, an infusion set developer.

In Aug 2022, Insulet Corporation, leader in tubeless insulin pump technology announced U.S. FDA clearance for automated Omnipod 5 insulin delivery system for children aged 2 years or above having type 1 diabetes.

The companies are raising the funding and investment to increase their market penetration. For instance, in January 2020, Virta had raised the USD 93 million Series C financing for increasing the reach of the digital diabetes product and reach.

Key Companies to Watch

Medtronic Plc:

Overview: Medtronic plc is an American company that operates in U.S. and manufactures and markets medical device headquarters in Minneapolis, US. It is operational in around 140 countries and 90,000 people are employed there.

Product Portfolio:

I-PORT ADVANCE: It is an injection port with painless insertion, as it leaves cannula under skin and with fewer punctures medications can be injected in every 3 days. It can be used by adults as well as children.

Key Developments: In Aug 2020, Medtronic, medical technology leader announced its acquisition of Companion Medical, InPen manufacturer- only U.S.FDA approved smart insulin pen system.

The global digital diabetes management market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Rising prevalence of diabetes
      • 4.1.1.2. Increasing technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of digital diabetes management devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis

6. By Product & Service

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service Segment
    • 6.1.2. Market Attractiveness Index, By Product & Service Segment
  • 6.2. Devices
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 6.2.1.3. Smart Glucose Meters
      • 6.2.1.4. Continuous Glucose Monitoring (CGM) Systems
      • 6.2.1.5. Smart Insulin Pens
      • 6.2.1.6. Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
  • 6.3. Digital Diabetes Management Apps
    • 6.3.1. Diabetes & Blood Glucose Tracking Apps
    • 6.3.2. Weight & Diet Management Apps
  • 6.4. Data Management Software & Platforms
  • 6.5. Others

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type Segment
    • 7.1.2. Market Attractiveness Index, By Device Type Segment
  • 7.2. Handheld Devices
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Wearable Devices

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Self/Home Healthcare
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Hospitals & Specialty Diabetes Clinics
  • 8.4. Academic & Research Institutes
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product & Services Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Medtronic Plc
    • 11.1.1. Company Overview
    • 11.1.2. Product & Service Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. F. Hoffmann-La Roche Dexcom, Inc.
  • 11.3. Dexcom, Inc.
  • 11.4. Ascensia Diabetes Care Holdings Ag.
  • 11.5. Abbott Laboratories
  • 11.6. B. Braun Melsungen AG
  • 11.7. Tidepool
  • 11.8. Glooko, Inc.
  • 11.9. Lifescan, Inc. (Subsidiary of Johnson & Johnson)
  • 11.10. Agamatrix, Inc.

LIST NOT EXHAUSTIVE

12. Global Digital Diabetes Management Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and End User
  • 12.3. Contact Us